Unlike PTCL, T-ALL shows less vulnerable to the cytotoxicity of HDAC inhibitors [23,24,25], suggesting that combination with other compounds is necessary to potentiate the efficacy of HDACi against T-ALL. Here, HDAC9 is linked to acute lymphoblastic leukemia.